↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
KKR removes **$1.46 billion** in medical device supply-chain visibility from public markets; contract renewals in Q2-Q3 2025 are the last pricing signal.
$5.7 billion
in cash
24% premium
to the thirty-day volume-weighted average
$1.46 billion
in revenue over the trailing twelve months with operating…
18%
The deal follows KKR's
KKR announced it will acquire Integer Holdings for $5.7 billion in cash, taking the medical device component manufacturer private in a transaction valued at $121 per share—a 24% premium to the thirty-day volume-weighted average. Integer, which manufactures batteries for cardiac devices and components for neurostimulators, generated $1.46 billion in revenue over the trailing twelve months with operating margins near 18%. The deal follows KKR's $13 billion take-private of Envision Healthcare in 2018 and its $2.9 billion acquisition of Avantor's biopharma services unit in 2023, both infrastructure plays beneath the brand layer of healthcare.
Integer holds 65% market share in rechargeable battery systems for implantable cardiac defibrillators and supplies components to Abbott, Boston Scientific, and Medtronic under multi-year contracts that renew through 2027. The company operates 15 manufacturing facilities across the U.S., Europe, and Asia, with 42% of revenue derived from cardiac rhythm management and 31% from neuromodulation. KKR's healthcare strategy head did not disclose debt-to-equity ratios for the transaction, but Integer carried $847 million in net debt as of the most recent quarter, implying an enterprise value near $6.5 billion and a valuation of 4.5x trailing revenue. That multiple sits 18% below the sector median for publicly traded device suppliers, which averaged 5.5x over the past six months.
The transaction removes price discovery from a segment allocators use to gauge supply-chain health in implantables. Integer's quarterly earnings provided forward visibility into device volumes at the three largest cardiac manufacturers, who collectively represent $48 billion in annual device revenue. With Integer private, that data evaporates from public filings. The move also concentrates component supply: KKR now controls Integer and holds a 28% stake in Avantor, creating cross-portfolio exposure to both raw materials and finished sub-assemblies in the medical supply chain. For family offices holding Boston Scientific or Abbott, this reduces the number of independent data points available to model device-volume growth. The deal is structured as an all-cash tender with financing from Barclays and JPMorgan, expected to close in the second half of 2025 pending regulatory clearance.
Operators should track Integer's next two quarterly filings before the deal closes, specifically contract renewals with Abbott and Boston Scientific that come due in Q2 and Q3 2025. Those renewals will surface pricing power—or lack thereof—before the company exits public view. Allocators modeling healthcare infrastructure plays should note that KKR's healthcare private equity fund is raising a targeted $7 billion vehicle, per SEC filings from January, with Integer likely the anchor asset. That fund structure implies a hold period of six to eight years, meaning Integer's margins and contract pricing will optimize for cash generation rather than revenue growth.
The Federal Trade Commission has 90 days from filing to issue a second request, with Barclays expecting clearance by August 2025 absent antitrust concerns. Integer's largest contracts contain change-of-control provisions that allow counterparties to renegotiate pricing within 180 days of a transaction close, a detail that will surface in Boston Scientific's Q3 2025 call.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor Boston Scientific and Abbott contract renewals through Q3 2025 before Integer exits public filings and forward visibility disappears.
For the operator
Track Integer's next two quarters for component pricing trends; KKR's hold structure prioritizes cash generation over growth, altering margin trajectory.
For the house
We are flagging this for the healthcare infrastructure theme; KKR's cross-portfolio control of Avantor and Integer warrants a materials-to-devices supply map.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.